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One of the great quests of contemporary medical research 
is the search for an improved tuberculosis vaccine—one 
that provides greater and more consistent protection 
against tuberculosis than the BCG vaccine can achieve. 
The stakes are high. The venture is costly and risky, but 
has a huge potential payoﬀ . A high-eﬃ  cacy vaccine 
could revolutionise control of tuberculosis, shifting the 
emphasis from treatment to prevention. As the case 
numbers slowly fall in high-burden countries, and as new 
strains of drug-resistant tuberculosis emerge, a novel 
and transformational technology for tuberculosis control 
would be cause for great celebration.1
US$70–100 million is spent on vaccine research for 
tuberculosis every year and the pipeline of candidate 
vaccines is now longer and wider than ever before.2–4 As 
each of the candidates moves from preclinical to clinical 
stages, passing tests for safety and immunogenicity, 
experi ments to assess eﬃ  cacy in human beings are 
major events.
Against this background, Michele Tameris and col-
leagues report in The Lancet results of a phase 2b trial in 
infants in South Africa of the vaccine modiﬁ ed Vaccinia 
virus Ankara expressing antigen 85A (MVA85A).5 
Although the primary objective of the trial was to 
assess safety, it also made a preliminary assessment of 
eﬃ  cacy—and many readers will go, with halted breath, 
straight to the conclusions about eﬃ  cacy. They will 
be confronted with results that are, on the face of it, 
disappointing, show ing little evidence of eﬃ  cacy in 
terms of prevention of tuberculosis or infection with 
Mycobacterium tuberculosis. 
Although the trial raised no concerns about safety, 
the absence of any detectable eﬃ  cacy presents the 
tuberculosis vaccine community with a serious 
challenge. However, the ﬁ ndings reported by Tameris 
and colleagues are not a terminal prognosis for 
MVA85A, or for any of the other tuberculosis vaccines 
in develop ment. To understand why, the results of this 
particular trial need to be put in a wider context.
Two main strategies exist for development of 
tuberculosis vaccines.6 The ﬁ rst is to replace the widely 
used BCG vaccine with an improved whole-organism 
vaccine, which is either a recombinant BCG or an 
attenuated strain of M tuberculosis. The second is to 
develop a subunit boosting vaccine, which is designed 
to enhance whatever protection is already provided by 
BCG. MVA85A is an example of the latter strategy. 
In their elegant randomised, placebo-controlled 
trial, Tameris and colleagues followed up 2794 BCG-
vaccinated infants for up to 37 months (median 24·6, 
IQR 19·2–28·1) in two nearly equal groups. 39 (2·8%) 
of 1395 infants in the placebo group (Candida skin 
test antigen) satisﬁ ed the primary deﬁ nition of active 
tuberculosis, of whom 20 were microbiologically 
conﬁ rmed. 32 (2·3%) of 1399 infants in the vaccine 
group (MVA85A) satisﬁ ed the primary deﬁ nition of 
active tuberculosis, of whom 22 were microbiologically 
conﬁ rmed. Thus, vaccine eﬃ  cacy was 17·3%, which was 
not distinguishable from zero (95% CI –31·9 to 48·2). 
Neither was there any evidence for protection against 
M tuberculosis infection, as determined by an in-vitro 
interferon γ release assay (QuantiFERON-TB Gold In-
tube; Cellestis, Australia). During the trial, 349 (13%) 
of 2792 participants became positive on this assay, 
171 (12%) in the placebo group and 178 (13%) in the 
vaccine group. The ratio of apparent infection to disease 
was thus about ﬁ ve to one considering all cases of 
tuberculosis, or eight to one for conﬁ rmed cases only.
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These results might provide little optimism that 
MVA85A will deliver a new tuberculosis vaccine. But 
this trial was designed to answer only one of a series of 
important questions about new tuberculosis vaccines. 
Before drawing any ﬁ rm conclusions, we need to answer 
several other questions. 
First, could MVA85A be eﬀ ective against infant and 
child hood tuberculosis when used independently of BCG? 
Substantial evidence shows that BCG protects young 
children against tuberculosis; so to seek yet more pro-
tection might be asking too much of MVA85A. This poses 
a major problem for tuberculosis vaccine research because 
BCG is recommended for infants in all countries with high 
burdens of tuberculosis. One of the explanations for the 
BCG vaccine’s poor performance in some populations is 
that exposure to other mycobacterial antigens can mask 
its eﬀ ect—perhaps BCG masked the eﬀ ect of MVA85A?7 
Second, in view of the variable performance of BCG 
in diﬀ erent populations, can we assume that the same 
results will be obtained with MVA85A in other popu-
lations? South Africa has been favoured for vaccine trials 
because the transmission rate of M tuberculosis and burden 
of disease are comparatively high. The question remains 
whether the characteristics that are responsible for this 
high burden somehow militate against immunisation. 
Third, could MVA85A, working as a booster to BCG, 
protect adolescents and adults against pulmonary 
tuberculosis in a way that it cannot protect infants? 
Immunologically naive infants and young children do 
not develop pulmonary tuberculosis in the same clinical 
form as adults, and adult pulmonary tuberculosis is the 
main target of tuberculosis control. 
Fourth, might this vaccine work if administered 
to people infected with HIV? MVA85A is also being 
tested in HIV-positive adults in Senegal and South 
Africa. If these trials are successful, MVA85A might 
be a replacement for BCG which, as a live-attenuated 
vaccine, is not recommended for people living with HIV.
Fifth, could MVA85A be eﬃ  cacious against severe 
forms of tuberculosis, including pulmonary tuberculosis, 
without preventing infection or mild forms of disease? 
A high eﬃ  cacy against severe disease could have been 
masked in this trial which, by use of invasive diagnostic 
methods including gastric lavage, detected relatively 
mild forms of tuberculosis infection or disease.  
Sixth, how does the eﬃ  cacy of MVA85A compare 
with other vaccine candidates now in phase 2b trials? 
The world eagerly awaits the next set of results on the 
eﬃ  cacy of two other subunit boosting vaccines, both 
from trials in South Africa: AERAS-402/Crucell Ad35 in 
infants and GlaxoSmithKline’s GSK M72 in adults.3
Finally, key questions remain about immunogenicity. 
The word itself might be misleading, insofar as it is 
used to describe any measurable immunological eﬀ ect, 
irrespective of the implications  for protection. MVA85A 
is described as modestly immunogenic because it 
generated moderate antigen-speciﬁ c Th1 and Th17 
responses (compared with other populations) although 
it showed no evidence of protection against infection or 
disease. A large bank of samples collected in the recent 
trial have yet to be examined and analysed—and might 
yet help to identify immunological factors that are 
characteristic of individuals who do and do not develop 
tuberculosis. The identiﬁ cation of a valid measure of 
protective immunity against tuberculosis would be a 
discovery of overwhelming importance.  
Apart from the spur to solve all these problems, 
the search for a new tuberculosis vaccine has other 
sources of inspiration. It remains an astonishing fact 
that children aged 5–10 years are very resistant to 
development of active tuberculosis.8 Is this resistance 
suggestive of an immunological mechanism that could 
be exploited for vaccine development? In preclinical 
research, investigations with animals continue to 
generate new and promising results. One example is 
H56, a vaccine that combines antigens characteristic of 
early infection and latency, and seems to protect mice 
against tuberculosis disease before and after exposure to 
infection.9 A vaccine that could protect everyone before 
and after infection is an epidemiologist’s dream.10
Now is a key moment in tuberculosis vaccine research. 
Trials such as that of Tameris and colleagues are at last 
generating hard evidence about protection against 
tuberculosis in human beings, the most important goal 
of immunisation. If the history of tuberculosis vaccine 
research teaches us anything, it is to expect surprises. We 
need to go on playing the high-stakes game.
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Folic acid fortiﬁ cation, instituted in the mid to late 
1990s in the USA and Canada, and now in more than 
50 countries,1 has been highly eﬀ ective for its intended 
purpose—to reduce the incidence of neural tube defects 
(eg, spina biﬁ da and anencephaly).2–4 However, lingering 
concerns about the safety of excess intake of folic acid 
still exist, particularly with respect to cancer.5
Why the concern? Folic acid—or rather the bioactive 
forms of folic acid (collectively ”folate”)—is required for 
de novo synthesis of thymidine, adenine, and guanine, 
three of the four nucleotides needed to assemble 
DNA. Because cancer cells, like all cells, synthesise 
DNA during mitosis, they require a supply of folate. 
Limitation of the supply of folate, or inhibition of folate 
metabolism (with anti-cancer drugs), slows or arrests 
proliferation of several forms of cancer. Conversely, the 
supply of cancer cells with extra folate can promote 
their proliferation;5–8 thus the concern that increased 
folate intake due to folic acid fortiﬁ cation, on top of 
dietary and supplemental folate consumption, could 
promote existing neoplasms.
The issue is complicated, however, because in non-
cancerous cells, folate can prevent or limit mutational 
events that initiate tumorigenic transformation. When 
folate is deﬁ cient, the supply of thymidine to insert 
into DNA is scarce, resulting in uracil misincorporation. 
When uracil is removed, holes are left behind in 
the DNA sequence, which ultimately leads to DNA 
strand breaks. Additionally, C→T mutations are more 
likely to occur when folate is deﬁ cient. Both events 
result in DNA damage that can foster tumorigenic 
transformation. Thus, folate has a putative two-
faced relationship with cancer: it can protect against 
initiation, but promote proliferation.
Is there epidemiological evidence for these dual eﬀ ects 
of folate? In 2007, Joel Mason and colleagues9 pub lished 
a controversial ecological study that suggested colorectal 
cancer incidence, which had been decreasing in the USA 
and Canada, increased temporarily after the institution of 
folic acid fortiﬁ cation in the two countries. Subsequently, 
the incidence rate began to decrease again.
One interpretation of these data is that folic acid 
fortiﬁ cation enhanced the proliferation and growth 
of preclinical neoplastic lesions, making them become 
clinically evident, and thus temporarily increasing 
apparent incidence. Then, the protective eﬀ ect of folate 
against neoplastic initiation kicked in, and incidence 
rates declined again. This interpretation has been 
challenged, however, by the claim that the increased 
incidence occurred too quickly after the start of folic 
acid fortiﬁ cation to be biologically plausible.10,11 This is a 
speculative statement, however, as the rate of neoplastic 
growth can be rapidly modulated by manipulation of 
micronutrient supply, at least in cell lines and rodents.6–8 
However, empirical data that excess micronutrient con-
sumption in man signiﬁ cantly accelerates neoplastic 
growth is lacking, and therefore this point of contention 
remains open to debate.
In The Lancet, Stein Emil Vollset and colleagues11 
present important new data that contribute to the 
debate regarding folic acid and cancer. The investigators 
conducted a meta-analysis of 13 randomised trials that 
Folic acid and cancer—where are we today?
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